1240TiPPhase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy. (23rd October 2018) - Lewis, K D; Fury, M G; Stankevich, E; Mathias, M; Mohan, K K; Li, S; Nunnink, K; Perry, C; Narwal, A